Quote:

---

“TAS-102 and bevacizumab will be administered for three of four weeks in a four-week cycle, and leronlimab (at doses of 350 mg or 700 mg) will be administered weekly. ”

---

That is almost certainly the dosing across the entire trial. The break of one week with the other two drugs is probably because of toxicity.

Quote:

---

Overall, 89.8% of the patients in the combination group and 81.3% in the FTD–TPI group had adverse events that were attributed by the investigator to FTD–TPI, and 48.4% of the patients in the combination group had bevacizumab-related events.
https://www.nejm.org/doi/full/10.1056/NEJMoa2214963

---

We've seen in our other cancer trials that leronlimab can stop and sometimes reverse tumor growth. I wonder how well it would do in a head to head comparison with TAS-102. If leronlimab does as good alone as the three drug combo we can downsize the massive treatment associated adverse events,